Author:
Jain Tania,Rampal Raajit K.
Reference58 articles.
1. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis;Tefferi;Blood,2014
2. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis;Tam;J Clin Oncol,2009
3. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure;Alhuraiji;Clin Case Rep,2018
4. KRT‑232, a first‑in‑class, murine double minute 2 inhibitor (MDM2i), for myelofibrosis (MF) relapsed or refractory (R/R) to janus‑associated kinase inhibitor (JAKi) treatment (TX);Al-Ali;EHA Library,2020
5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med,2012
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献